Bank of Nova Scotia
OVID icon

Bank of Nova Scotia’s Ovid Therapeutics OVID Stock Holding History

Bank of Nova Scotia’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-44,152
Closed -$135K – 1051
2024
Q1 		$135K Hold
44,152
– – ﹤0.01% 973
2023
Q4 		$142K Hold
44,152
– – ﹤0.01% 974
2023
Q3 		$170K Buy
44,152
+133
+0.3% +$478 ﹤0.01% 960
2023
Q2 		$144K Buy
44,019
+663
+2% +$2.25K ﹤0.01% 987
2023
Q1 		$112K Sell
43,356
-2,125
-5% -$5.04K ﹤0.01% 1109
2022
Q4 		$84.6K Buy
45,481
+159
+0.4% +$271 ﹤0.01% 1142
2022
Q3 		$83K Buy
45,322
+230
+0.5% +$481 ﹤0.01% 1125
2022
Q2 		$97K Sell
45,092
-2,258
-5% -$5.46K ﹤0.01% 1140
2022
Q1 		$149K Buy
47,350
+5,124
+12% +$16.1K ﹤0.01% 1158
2021
Q4 		$136K Buy
+42,226
New +$145K ﹤0.01% 1184

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of Nova Scotia's OVID Position: Q2 2024 in Review

Bank of Nova Scotia sold out of Ovid Therapeutics (OVID) in Q2 2024, closing a stake of 44,152 shares — an estimated $135K sold.

Bank of Nova Scotia first reported a position in OVID in Q4 2021 and held it in 10 quarters. The position peaked at $170K in Q3 2023. 74 funds tracked by Wall St. Rank hold OVID as of Q2 2024.

  • Bank of Nova Scotia reported no remaining Ovid Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bank of Nova Scotia sold 44,152 Ovid Therapeutics shares in Q2 2024, an estimated $135K.
  • Bank of Nova Scotia first reported a position in Ovid Therapeutics in Q4 2021 and held it in 10 quarters.
  • Bank of Nova Scotia's Ovid Therapeutics position peaked at $170K in Q3 2023.
  • 74 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2024.

Based on Bank of Nova Scotia's 13F filing for Q2 2024, filed 14 Aug 2024.